BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in ...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an ...